EA201990413A1 - Способ лечения печеночной энцефалопатии - Google Patents

Способ лечения печеночной энцефалопатии

Info

Publication number
EA201990413A1
EA201990413A1 EA201990413A EA201990413A EA201990413A1 EA 201990413 A1 EA201990413 A1 EA 201990413A1 EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A EA201990413 A EA 201990413A EA 201990413 A1 EA201990413 A1 EA 201990413A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatic encephalopathy
treating hepatic
treating
encephalopathy
biotin
Prior art date
Application number
EA201990413A
Other languages
English (en)
Inventor
Фредерик Седель
Original Assignee
Меддэй Фармасьютикалз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Меддэй Фармасьютикалз filed Critical Меддэй Фармасьютикалз
Publication of EA201990413A1 publication Critical patent/EA201990413A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к применению биотина в суточной дозе по меньшей мере 100 мг для лечения печеночной энцефалопатии.
EA201990413A 2016-07-29 2017-07-28 Способ лечения печеночной энцефалопатии EA201990413A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
EA201990413A1 true EA201990413A1 (ru) 2019-06-28

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990413A EA201990413A1 (ru) 2016-07-29 2017-07-28 Способ лечения печеночной энцефалопатии

Country Status (23)

Country Link
US (2) US10117854B2 (ru)
EP (2) EP3275439A1 (ru)
JP (1) JP2019522030A (ru)
KR (1) KR20190034550A (ru)
AU (1) AU2017303346A1 (ru)
BR (1) BR112019001178A2 (ru)
CA (1) CA3031302A1 (ru)
CY (1) CY1122348T1 (ru)
DK (1) DK3319601T3 (ru)
EA (1) EA201990413A1 (ru)
ES (1) ES2751154T3 (ru)
HK (1) HK1254833B (ru)
HR (1) HRP20191798T1 (ru)
HU (1) HUE046590T2 (ru)
IL (1) IL264460B (ru)
LT (1) LT3319601T (ru)
MA (1) MA42419B1 (ru)
ME (1) ME03520B (ru)
PL (1) PL3319601T3 (ru)
PT (1) PT3319601T (ru)
RS (1) RS59300B1 (ru)
SI (1) SI3319601T1 (ru)
WO (1) WO2018020010A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX2018004788A (es) * 2018-04-18 2019-10-21 Alparis Sa De Cv Nuevas fases solidas de rifaximina.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol Pharmazeutische Vertr Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20130004545A1 (en) 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
IL264460A (en) 2019-02-28
IL264460B (en) 2021-06-30
HK1254833B (zh) 2020-05-22
ME03520B (me) 2020-04-20
LT3319601T (lt) 2019-11-11
US10328059B2 (en) 2019-06-25
PT3319601T (pt) 2019-09-18
US20190070150A1 (en) 2019-03-07
KR20190034550A (ko) 2019-04-02
EP3319601B1 (en) 2019-08-28
HUE046590T2 (hu) 2020-03-30
MA42419B1 (fr) 2019-11-29
WO2018020010A1 (en) 2018-02-01
CA3031302A1 (en) 2018-02-01
BR112019001178A2 (pt) 2019-04-30
ES2751154T3 (es) 2020-03-30
US10117854B2 (en) 2018-11-06
EP3275439A1 (en) 2018-01-31
RS59300B1 (sr) 2019-10-31
AU2017303346A1 (en) 2019-01-31
DK3319601T3 (da) 2019-11-18
HRP20191798T1 (hr) 2019-12-27
SI3319601T1 (sl) 2019-11-29
EP3319601A1 (en) 2018-05-16
PL3319601T3 (pl) 2020-06-29
MA42419A (fr) 2018-05-16
JP2019522030A (ja) 2019-08-08
CY1122348T1 (el) 2021-01-27
US20180214417A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CL2016002144A1 (es) Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2017002781A1 (es) Métodos de tratamiento de enfermedad de alzheimer
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA201791110A1 (ru) Сублингвальное введение рилузола
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
DOP2017000111A (es) Inhibidor de cinasa aurora a
TR201901687T4 (tr) Hepatik ensefalopati tedavisinde kullanıma yönelik steroid bileşik.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CY1122348T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της ηπατικης εγκεφαλοπαθειας
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
MY178971A (en) Triaminopyrimidine compounds useful for preventing or treating malaria
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CL2020000586A1 (es) Moduladores de la expresión de enac.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
MX2016008968A (es) Compuestos organicos.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018012193A (es) Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.